8
A randomized double-blind phase III trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD/Doxil®/Caelyx®) in combination versus PLD in participants with platinum-resistant ovarian cancer (PROCEED) (NCT01170650)
Saturday, March 28, 2015: 10:58 AM
International Ballroom (Hilton Chicago)
A. M. Oza1, I. B. Vergote2, L. G. Gilbert, Lucy3, P. Ghatage4, A. Lisyankaya5, S. Ghamande6, S. K. Chambers7, J. A. Arranz8, D. M. Provencher9, P. Bessette10, A. Amnon11, J. Symanowski12, R. T. Penson13, R. W. Naumann12 and R. Clark14
1Princess Margaret Hospital, Toronto, ON, Canada, 2University Hospital Leuven, Leuven, Belgium, 3McGill University, Montreal, QC, Canada, 4Tom Baker Cancer Centre, Calgary, AB, Canada, 5St. Petersburg City Oncology Hospital, Saint Petersburg, Russia, 6Georgia Regents University, Augusta, GA, 7University of Arizona Cancer Center, Tucson, AZ, 8Hospital General, Madrid, Spain, 9Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, 10University of Sherbrooke, Quebec, QC, Canada, 11Rambam Medical Center, Hafia, Israel, 12Levine Cancer Institute, Charlotte, NC, 13Massachusetts General Hospital/Harvard University, Boston, MA, 14Endocyte, Inc., Dover, DE
